Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120ctn in pancreatic cancer

被引:49
作者
Mayerle, J
Friess, H
Büchler, MW
Schnekenburger, J
Weiss, FU
Zimmer, KP
Domschke, W
Lerch, MM
机构
[1] Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany
[2] Univ Munster, Dept Med B, D-4400 Munster, Germany
[3] Univ Munster, Dept Pediat, D-4400 Munster, Germany
关键词
D O I
10.1053/gast.2003.50142
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cell adhesion proteins have been implicated as tumor suppressors because they prevent malignant cells from dissociating their cell contacts. We have studied the role of p120(ctn), a recently discovered member of the cadherin/catenin family, in human pancreatic cancer. Methods: In 32 resection specimens of pancreatic adenocarcinoma and 10 control samples the expression of p120(ctn) was studied by Northern blot, immunocytochemistry, and immunogold electron microscopy. Patient survival data, tumor grading, and staging were correlated to the experimental results. In PaTu 8889 T pancreatic cancer cells, p120(ctn) expression was suppressed with 21-nucleotide small interfering RNA (siRNA) duplexes and proliferation was determined by bromodeoxyuridine (BrdU) incorporation. Results: In pancreatic cancer p120(ctn) messenger RNA (mRNA) was increased 3- to 4-fold. Although p120(ctn) was localized exclusively at cell contacts in controls it was found in the cytosol and nucleus of pancreatic cancer cells. This redistribution correlated to the degree of tumor dedifferentiation but was independent of tumor stage. The mean survival of patients with predominant membrane localization of p120(ctn) was 24 +/- 7 (SEM) months vs. 9 +/- 2 months for patients with predominant cytoplasmic p120(ctn) expression (P < 0.05). Silencing of p120(ctn) with siRNA duplexes reduced pancreatic cancer cell growth by 40%. Conclusions: Up-regulation, cytoplasmic redistribution, and nuclear import of p120(ctn) are associated with a more malignant phenotype of pancreatic cancer. This study further represents conclusive evidence for a direct involvement of p120(ctn) in malignant tumor cell proliferation. Both p120(ctn)-defective tumor cell contacts and p120(ctn)-mediated growth signals appear to contribute to the aggressive spread of pancreatic cancer.
引用
收藏
页码:949 / 960
页数:12
相关论文
共 53 条
[31]   A causal role for E-cadherin in the transition from adenoma to carcinoma [J].
Perl, AK ;
Wilgenbus, P ;
Dahl, U ;
Semb, H ;
Christofori, G .
NATURE, 1998, 392 (6672) :190-193
[32]   The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor [J].
Prokhortchouk, A ;
Hendrich, B ;
Jorgensen, H ;
Ruzov, A ;
Wilm, M ;
Georgiev, G ;
Bird, A ;
Prokhortchouk, E .
GENES & DEVELOPMENT, 2001, 15 (13) :1613-1618
[33]  
REAL FX, 1996, PANCREATIC CANC MOL, P3
[34]   IDENTIFICATION OF A NEW CATENIN - THE TYROSINE KINASE SUBSTRATE P120(CAS) ASSOCIATES WITH E-CADHERIN COMPLEXES [J].
REYNOLDS, AB ;
DANIEL, J ;
MCCREA, PD ;
WHEELOCK, MJ ;
WU, J ;
ZHANG, Z .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (12) :8333-8342
[35]  
REYNOLDS AB, 1992, ONCOGENE, V7, P2439
[36]  
SCHIPPER JH, 1999, CANCER RES, V51, P6328
[37]   ASSOCIATION OF P120, A TYROSINE KINASE SUBSTRATE, WITH E-CADHERIN/CATENIN COMPLEXES [J].
SHIBAMOTO, S ;
HAYAKAWA, M ;
TAKEUCHI, K ;
HORI, T ;
MIYAZAWA, K ;
KITAMURA, N ;
JOHNSON, KR ;
WHEELOCK, MJ ;
MATSUYOSHI, N ;
TAKEICHI, M ;
ITO, F .
JOURNAL OF CELL BIOLOGY, 1995, 128 (05) :949-957
[38]  
Shimazui T, 1996, CANCER RES, V56, P4154
[39]   Differential nuclear translocation and transactivation potential of β-catenin and plakoglobin [J].
Simcha, I ;
Shtutman, M ;
Salomon, D ;
Zhurinsky, J ;
Sadot, E ;
Geiger, B ;
Ben-Ze'ev, A .
JOURNAL OF CELL BIOLOGY, 1998, 141 (06) :1433-1448
[40]   Identification of a new human catenin gene family member (ARVCF) from the region deleted in velo-cardio-facial syndrome [J].
Sirotkin, H ;
ODonnell, H ;
DasGupta, R ;
Halford, S ;
StJore, B ;
Puech, A ;
Parimoo, S ;
Morrow, B ;
Skoultchi, A ;
Weissman, SM ;
Scambler, P ;
Kucherlapati, R .
GENOMICS, 1997, 41 (01) :75-83